Table 2.
Baseline patient characteristics.
Characteristic | Study Population (n = 61) |
Sensitive Patients (n = 38) |
Resistant Patients (n = 23) |
p-Value |
---|---|---|---|---|
N (%) | N (%) | N (%) | ||
Sex | ||||
Male | 40 (65.6%) | 32 (84%) | 8 (34.8%) | <0.001 |
Female | 21 (34.4%) | 6 (16%) | 15 (65.2%) | |
Age | ||||
<75 | 43 (70.5%) | 26 (68.4%) | 17 (73.9%) | 0.649 |
≥75 | 18 (29.5%) | 12 (31.6%) | 6 (26.1%) | |
Mean Age | 67.7 | 66.9 | ||
Performance status (ECOG) | ||||
0 | 31 (50.8%) | 24 (63.2%) | 7 (30.4%) | 0.013 |
1–2 | 30 (49.2%) | 14 (36.8%) | 16 (69.6%) | |
Smoking habit | ||||
Never smokers | 24 (39.3%) | 13 (34.2%) | 11 (47.8%) | 0.291 |
Current or former smokers | 37 (60.7%) | 25 (65.8%) | 12 (52.2%) | |
Tumor side | ||||
Right | 24 (39.4%) | 15 (39.5%) | 9 (39.2%) | |
Left | 20 (32.7%) | 13 (34.2%) | 7 (30.4 %) | 0.634 |
Rectal | 16 (26.3%) | 10 (26.3%) | 6 (26.1%) | |
Jejunum | 1 (1.6%) | 0 | 1 (4.3%) | |
Number of metastatic sites | ||||
1 | 30 (49.2%) | 18 (47.4%) | 12 (52.3%) | 0.716 |
≥2 | 31 (50.8%) | 20 (52.6%) | 11 (47.7%) | |
Time to metastases | ||||
Synchronous | 38 (62.3%) | 27 (71.1%) | 11 (47.8%) | 0.070 |
Metachronous | 23 (37.7%) | 11 (28.9%) | 12 (52.2%) | |
Primary resected | ||||
Yes | 49 (80.3%) | 32 (84.2%) | 17 (73.9%) | 0.327 |
No | 12 (19.7%) | 6 (15.8%) | 6 (26.1%) | |
Previous lines of treatment | ||||
0 | 24 (39.3%) | 18 (47.4%) | 6 (26.1%) | |
1 | 32 (52.5%) | 17 (44.7%) | 15 (65.2%) | 0.246 |
≥2 | 5 (8.2%) | 3 (7.9%) | 2 (8.7%) | |
Type of anti-EGFR | ||||
Cetuximab | 33 (54.1%) | 21 (55.3%) | 12 (52.2%) | 0.814 |
Panitumumab | 28 (45.9%) | 17 (44.7%) | 11 (47.8%) | |
Combination QT | ||||
FOLFOX | 18 (29.5%) | 14 (36.8 %) | 4 (17.4%) | |
Irinotecan scheme | 40 (65.6%) | 23 (60.6%) | 17 (73.9%) | 0.192 |
Monotherapy | 3 (4.9%) | 1 (2.6 %) | 2 (8.7%) | |
PFS (months) | 18.8 | 4.7 | ||
OS (months) | 41.2 | 17.2 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; OS, overall survival; PFS, progression-free survival. p-values below 0.05 are highlighted in bold.